Publication: Strategies to improve chimeric antigen receptor therapies for neuroblastoma
2
Issued Date
2020-12-01
Resource Type
ISSN
2076393X
Other identifier(s)
2-s2.0-85097949652
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Vaccines. Vol.8, No.4 (2020), 1-28
Suggested Citation
Piamsiri Sawaisorn, Korakot Atjanasuppat, Usanarat Anurathapan, Somchai Chutipongtanate, Suradej Hongeng Strategies to improve chimeric antigen receptor therapies for neuroblastoma. Vaccines. Vol.8, No.4 (2020), 1-28. doi:10.3390/vaccines8040753 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/60485
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Strategies to improve chimeric antigen receptor therapies for neuroblastoma
Other Contributor(s)
Abstract
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. Chimeric antigen receptors (CARs) are among the curative immunotherapeutic approaches that exploit the antigen specificity and cytotoxicity function of potent immune cells against cancers. Neuroblastomas, the most common extracranial pediatric solid tumors with diverse characteristics, could be a promising candidate for using CAR therapies. Several methods harness CAR-modified cells in neuroblastoma to increase therapeutic efficiency, although the assessment has been less successful. Regarding the improvement of CARs, various trials have been launched to overcome insufficient capacity. However, the reasons behind the inadequate response against neuroblastoma of CAR-modified cells are still not well understood. It is essential to update the present state of comprehension of CARs to improve the efficiency of CAR therapies. This review summarizes the crucial features of CARs and their design for neuroblastoma, discusses challenges that impact the outcomes of the immunotherapeutic competence, and focuses on devising strategies currently being investigated to improve the efficacy of CARs for neuroblastoma immunotherapy.